Subclinical Impairment of Ovarian Reserve in Systemic Lupus Erythematosus Patients with Normal Menstruation Not Using Alkylating Therapy
Publication: Journal of Women's Health
Volume 22, Issue Number 12
Abstract
Background: Disease activity is a major factor in menstrual disorders in systemic lupus erythematosus (SLE) patients not receiving alkylating therapy. However, the ovarian reserve of SLE women with normal menstruation is still unclear.
Methods: Twenty-three SLE patients naïve to cytotoxic agents (SLE group) and nineteen SLE patients receiving current or previous cyclophosphamide (CTX) therapy (without other cytotoxic agents; SLE-CTX group) were enrolled. Twenty-one age-matched healthy women served as controls. All patients and controls had a regular menstrual cycle. Basal hormone levels, including follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), and anti-Müllerian hormone (AMH), and antral follicle count (AFC) were analyzed in the two study groups and compared with the control group.
Results: No significant differences were found between the SLE, SLE-CTX, and control groups in age, body mass index (BMI), and basal FSH and LH levels. The E2 (P=0.023) levels were high and the AMH (P=0.000) values and AFC (P=0.001) were significantly lower in the SLE and SLE-CTX groups compared to control. However, these values were similar between the SLE and SLE-CTX groups.
Conclusion: SLE patients not receiving alkylating therapy who had normal menstruation and short illness duration still had an impaired ovarian reserve.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Shabanova SSAnanieva LPAlekberova ZSGuzov II. Ovarian function and disease activity in patients with systemic lupus erythematosusClin Exp Rheumatol200826436-441.1. Shabanova SS, Ananieva LP, Alekberova ZS, Guzov II. Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin Exp Rheumatol 2008;26:436–441.
2.
Pasoto SGMendonça BBBonfá E. Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: Clinical, hormonal and therapeutic associationsLupus200211175-180.2. Pasoto SG, Mendonça BB, Bonfá E. Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: Clinical, hormonal and therapeutic associations. Lupus 2002;11:175–180.
3.
Fatnoon NNAzarisman SMZainal D. Prevalence and risk factors for menstrual disorders among systemic lupus erythematosus patientsSingapore Med J200849413-418.3. Fatnoon NN, Azarisman SM, Zainal D. Prevalence and risk factors for menstrual disorders among systemic lupus erythematosus patients. Singapore Med J 2008; 49:413–418.
4.
Gonzalez-Crespo MRGomez-Reino JJMerino R et al. Menstrual disorders in girls with systemic lupus erythematosus treated with cyclophosphamideBr J Rheumatol199534737-741.4. Gonzalez-Crespo MR, Gomez-Reino JJ, Merino R, et al. Menstrual disorders in girls with systemic lupus erythematosus treated with cyclophosphamide. Br J Rheumatol 1995;34:737–741.
5.
van Beek Rvan den Heuvel-Eibrink MLaven J et al. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhoodJ Clin Endocrinol Metab2007923869-3874.5. van Beek R, van den Heuvel-Eibrink M, Laven J, et al. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood. J Clin Endocrinol Metab 2007;92:3869–3874.
6.
van Rooij ITonkelaar IBroekmans F et al. Anti-mullerian hormone is a promising predictor for the occurrence of the menopausal transitionMenopause200411601-606.6. van Rooij I, Tonkelaar I, Broekmans F, et al. Anti-mullerian hormone is a promising predictor for the occurrence of the menopausal transition. Menopause 2004;11:601–606.
7.
Fanchin RSchonauer LRighini CGuibourdenche JFrydman RTaieb J. Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH, and LH on day 3Hum Reprod200318323-327.7. Fanchin R, Schonauer L, Righini C, Guibourdenche J, Frydman R, Taieb J. Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH, and LH on day 3. Hum Reprod 2003;18:323–327.
8.
Seifer DMacLaughlin DChristian BFeng BShelden R. Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cyclesFertil Steril200277468-471.8. Seifer D, MacLaughlin D, Christian B, Feng B, Shelden R. Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 2002;77:468–471.
9.
Muttukrishna SMcGarrigle HWakim RKhadum IRanieri DSerhal P. Antral follicle count, anti-mullerian hormone and inhibin B: Predictors of ovarian response in assisted reproductive technology?Br J Obstet Gynecol20051121384-1390.9. Muttukrishna S, McGarrigle H, Wakim R, Khadum I, Ranieri D, Serhal P. Antral follicle count, anti-mullerian hormone and inhibin B: Predictors of ovarian response in assisted reproductive technology? Br J Obstet Gynecol 2005;112:1384–1390.
10.
Ficicioglu CKutlu TBaglam EBakacak Z. Early follicular antimullerian hormone as an indicator of ovarian reserveFertil Steril200685592-596.10. Ficicioglu C, Kutlu T, Baglam E, Bakacak Z. Early follicular antimullerian hormone as an indicator of ovarian reserve. Fertil Steril 2006;85:592–596.
11.
Anderson RThemmen AAl-Qahtani AGroome NCameron D. The effects of chemotherapy and long-term gonadotropin suppression on the ovarian reserve in premenopausal women with breast cancerHum Reprod2006212583-2592.11. Anderson R, Themmen A, Al-Qahtani A, Groome N, Cameron D. The effects of chemotherapy and long-term gonadotropin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 2006;21:2583–2592.
12.
Kwee JElting MESchats RMcDonnell JLambalk CB. Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilizationReprod Biol Endocrinol2007155-9.12. Kwee J, Elting ME, Schats R, McDonnell J, Lambalk CB. Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilization. Reprod Biol Endocrinol 2007;15:5–9.
13.
Hale GEHughes CLBurger HGRobertson DMFraser IS. Atypical estradiol secretion and ovulation patterns caused by luteal out-of-phase (LOOP) events underlying irregular ovulatory menstrual cycles in the menopausal transitionMenopause20091650-59.13. Hale GE, Hughes CL, Burger HG, Robertson DM, Fraser IS. Atypical estradiol secretion and ovulation patterns caused by luteal out-of-phase (LOOP) events underlying irregular ovulatory menstrual cycles in the menopausal transition. Menopause 2009;16:50–59.
14.
Saketos MSharma NSantoro NF. Suppression of the hypothalamic-pituitary- ovarian axis in normal women by glucocorticoidsBiol Reprod1993491270-1276.14. Saketos M, Sharma N, Santoro NF. Suppression of the hypothalamic-pituitary- ovarian axis in normal women by glucocorticoids. Biol Reprod 1993;49: 1270–1276.
15.
Gallant CKenny P. Oral glucocorticoids and their complications. A reviewJ Am Acad Dermatol198614161-177.15. Gallant C, Kenny P. Oral glucocorticoids and their complications. A review. J Am Acad Dermatol 1986;14:161–177.
16.
Morrow JNelson LWatts RIsenberg D. Systemic lupus erythematosusAutoimmune rheumatic diseaseOxfordOxford University Press199956-103.16. Morrow J, Nelson L, Watts R, Isenberg D. Systemic lupus erythematosus. In: Autoimmune rheumatic disease. Oxford: Oxford University Press, 1999:56–103.
17.
Mignot MHSchoemaker JKleingeld MRao BRDrexhage HA. Premature ovarian failure. The association with autoimmunityEur J Obstet Reprod Biol19893059-65.17. Mignot MH, Schoemaker J, Kleingeld M, Rao BR, Drexhage HA. Premature ovarian failure. The association with autoimmunity. Eur J Obstet Reprod Biol 1989;30:59–65.
18.
Moncayo-Naveda HMoncayo RBenz RWolf ALauritzen C. Organ-specific antibodies against ovary in patients with systemic lupus erythematosusAm J Obstet Gynecol19891601227-1229.18. Moncayo-Naveda H, Moncayo R, Benz R, Wolf A, Lauritzen C. Organ-specific antibodies against ovary in patients with systemic lupus erythematosus. Am J Obstet Gynecol 1989;160:1227–1229.
19.
Wheatcroft NJSalt CMilford-Ward ACooke IDWeetman AP. Identification of ovarian antibodies by immunofluorescence, enzyme-linked immunosorbent assay or immunoblotting in premature ovarian failureHum Reprod1997122617-2622.19. Wheatcroft NJ, Salt C, Milford-Ward A, Cooke ID, Weetman AP. Identification of ovarian antibodies by immunofluorescence, enzyme-linked immunosorbent assay or immunoblotting in premature ovarian failure. Hum Reprod 1997;12: 2617–2622.
20.
Lubovsky JVisintin JBoyers SAsari TCaldwell BdeCheney A. Ovarian antibodies detected by immobilized antigen immunoassay in patients with premature ovarian failureJ Clin Endocrinol Metab19907069-74.20. Lubovsky J, Visintin J, Boyers S, Asari T, Caldwell B, deCheney A. Ovarian antibodies detected by immobilized antigen immunoassay in patients with premature ovarian failure. J Clin Endocrinol Metab 1990;70:69–74.
21.
Lubovsky JLlanes BDavies SBinor ZRadwanska EPong R. Ovarian autoimmunity: Greater frequency of autoantibodies in premature menopause and unexplained infertility than in general populationClin Immunol199990368-374.21. Lubovsky J, Llanes B, Davies S, Binor Z, Radwanska E, Pong R. Ovarian autoimmunity: Greater frequency of autoantibodies in premature menopause and unexplained infertility than in general population. Clin Immunol 1999;90:368–374.
22.
Chernyshov VPRadysh TVGura IVTatarchuk TPKhominskaya ZB. Immune disorders in women with premature ovarian failure in initial periodAm J Reprod Immunol200146220-225.22. Chernyshov VP, Radysh TV, Gura IV, Tatarchuk TP, Khominskaya ZB. Immune disorders in women with premature ovarian failure in initial period. Am J Reprod Immunol 2001;46:220–225.
23.
Roeiy AValesini GFriberg J et al. Autoantibodies and common idiotypes in men and women with sperm antibodiesAm J Obstet Gynecol1988158596-603.23. Roeiy A, Valesini G, Friberg J, et al. Autoantibodies and common idiotypes in men and women with sperm antibodies. Am J Obstet Gynecol 1988;158:596–603.
24.
Lanir NZilberman MYron ITennenbaum GShechter YBrenner B. Reactivity patterns of antiphospholipid antibodies and endothelial cells: effect of antiendothelial antibodies on cell migrationJ Lab Clin Med1998131548-556.24. Lanir N, Zilberman M, Yron I, Tennenbaum G, Shechter Y, Brenner B. Reactivity patterns of antiphospholipid antibodies and endothelial cells: effect of antiendothelial antibodies on cell migration. J Lab Clin Med 1998;131:548–556.
25.
Mizutani HKurata YKosugi S et al. Monoclonal anticardiolipin autoantibodies established from the (New Zealand white3BXSB)F1 mouse model of antiphospholipid syndrome cross-react with oxidized low-density lipoproteinArthritis Rheum1995381382-1388.25. Mizutani H, Kurata Y, Kosugi S, et al. Monoclonal anticardiolipin autoantibodies established from the (New Zealand white3BXSB)F1 mouse model of antiphospholipid syndrome cross-react with oxidized low-density lipoprotein. Arthritis Rheum 1995;38:1382–1388.
26.
Delgado Alves JKumar SIsenberg DA. Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndromeRheumatology (Oxford)200342893-899.26. Delgado Alves J, Kumar S, Isenberg DA. Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford). 2003;42:893–899.
27.
Aikawa NESallum AMPereira RM et al. Subclinical impairment of ovarian reserve in juvenile systemic lupus erythematosus after cyclophosphamide therapyClin Exp Rheumatol201230445-449.27. Aikawa NE, Sallum AM, Pereira RM, et al. Subclinical impairment of ovarian reserve in juvenile systemic lupus erythematosus after cyclophosphamide therapy. Clin Exp Rheumatol 2012;30:445–449.
28.
Al-Maini MHMountz JDAl-Mohri HA et al. Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosusLupus20009132-139.28. Al-Maini MH, Mountz JD, Al-Mohri HA, et al. Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus. Lupus 2000;9:132–139.
29.
Lawrenz BHenes JHenes M et al. Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: evaluation by using anti-Muellerian hormoneLupus2011201193-1197.29. Lawrenz B, Henes J, Henes M, et al. Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: evaluation by using anti-Muellerian hormone. Lupus 2011;20:1193–1197.
Information & Authors
Information
Published In
Journal of Women's Health
Volume 22 • Issue Number 12 • December 2013
Pages: 1023 - 1027
PubMed: 24283710
Copyright
Copyright 2013, Mary Ann Liebert, Inc.
History
Published in print: December 2013
Published online: 27 November 2013
Topics
Authors
Disclosure Statement
No competing financial interests exist.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.